Inland Peptides
Inland Peptides

Thymosin Beta-4

Research Snapshot Last reviewed October 2026
No

Approved by the FDA for human use

Yes

Studied in human clinical trials

Yes

Published human research

Yes

Published animal research

Primary research areas
  • Eye surface injury
  • wound healing
  • cardiac repair

Overview

Thymosin beta-4 is a naturally occurring peptide made of 43 amino acids. It helps cells move during tissue repair. This page covers the full-length peptide, rather than products sold as TB-500 fragments.

Thymosin Beta-4 is not approved by the Food and Drug Administration for human use, and no prescription version exists. It should only be used within an approved clinical study and never taken without a doctor’s authorization.

What is it being studied for?

Researchers have studied thymosin beta-4 as eye drops for dry eye and damage to the eye’s surface. Other studies examine wound healing and heart tissue repair.

Thymosin beta-4 binds actin, which helps cells change shape and move.

What has research found?

A randomized study found that thymosin beta-4 eye drops improved measures of dry eye. Another study compared the drops with existing treatments.

Animal studies found faster skin wound repair in diabetic and aged mice.

The human findings described here concern eye drops, not injected thymosin beta-4.

FDA status and development history

Thymosin beta-4 was identified in the 1980s. RegeneRx has developed an eye-drop formulation called RGN-259. It is not FDA-approved for human use.